RERA & DTCP Approved projects

Pharma city phase-I by 2018-end

Quote:

The State Government has resolved to operationalise the first phase of the Pharma City project coming up at Mucherla in Ranga Reddy district before the end of 2018.

Industries Minister K.T. Rama Rao said the draft master plan for the prestigious project, expected to see investments to the tune of ₹ 75,000 crore and create one lakh direct and two lakh indirect jobs, was under preparation even as the Government embarked upon acquiring land for the project. An extent of 5,646 acres was already under the possession of the Telangana State Industrial Infrastructure Corporation.

The Government had sought a loan of ₹ 750 crore from the HUDCO for acquiring land for Pharma City of which ₹ 350 crore had already been released. The Government had so far paid ₹ 231.21 crore towards land acquisition costs. Another ₹ 3,100 crore loan was sought from the Asian Infrastructure Bank and the Government was hopeful of receiving the assistance soon, the Minister said in reply to a query during the Question Hour in the Legislative Assembly on Monday.

Zero liquid discharge

The Opposition Congress raised questions relating to the discrimination in payment of compensation for the acquired land and also sought explanation about the necessary safeguards that were being incorporated in the pharma city which was under the “Orange and Red” category industry. The Congress members raised objection to the Government’s failure to take the consent of the people in the area earmarked for the project which was mandatory in case of setting up of red category industries. The Minister said the Government was working out modalities to put in place zero liquid discharge systems for the project and was planning to set up common effluent treatment plants with a capacity of 250 million litres a day.

There would be no compromise on treating the solid wastes too and necessary safeguards would all be put in place. The Government was planning to conduct gram sabhas once the environmental impact assessment study was complete, he said advising the members not to make irrational claims that were not warranted at this juncture when several companies were venturing to put in investments in the project.

Assuring the members that the Government would take the MLAs into confidence, he advised them not to raise alarm about the project and the criticism on the prestigious project.

In giant leap, 350 firms to set up shop in Phase-I of Pharma City

Quote:

Over 350 micro, small and medium enterprises are likely to set up projects in the first phase of the proposed Pharma City on the outskirts of Hyderabad, including about 120 big players. The government will allot land for pharma companies soon as the master plan for 12,500-acre Pharma City is expected to be ready by the end of January.

A conceptual plan for the Telangana government's ambitious Pharma City project, proposed at Mucherla in Rangareddy district, has already been prepared by Singapore-based Surbana Jurong Private Ltd. Finer details of the master plan are being readied through a photogrammetry survey, in which photographs are used to map and ascertain measurements and other details.

"The tentative land allotment for the companies will begin from next month and will be completed by April 2017. But actual construction will start only after getting environmental clearance from the Ministry of Environment and Forests," principal secretary (industries) Arvind Kumar told TOI.

While some pharma majors have sought as much as 200 to 300 acres for their firms, other smaller industries have asked for only 1,000 square metres.

The government will allot the land based on investment and category of applicants. Many of the companies have approached the industries department through Bulk Drug Manufacturers Associations and other organisations, Kumar said.

Of the total 12,500 acres, Phase I of Pharma City will come up on 6,000 acres for which land acquisition has been completed by Telangana State Industrial Infrastructure Corporation (TSIIC) with about Rs740 crore being spent both for the Pharma City and another manufacturing zone at Zaheerabad. While the Zaheerabad project has already been given National Investment Manufacturing Zone (NIMZ) status, the Pharma City has received in-principle approval.

To speed up the project, the government has formed a special purpose vehicle 'Hyderabad Pharma City Limited' to oversee the project.

Officials said top priority is being given to meet costs under the heads of physical and environmental protection as well as civil infrastructure at the Pharma City. These are expected to cost about Rs10,000 crore. "Road networks will be improved for better connectivity, especially to the Outer Ring Road, the proposed Regional Ring Road along with multi-modal transit system (MMTS). An air strip will also be developed at the Pharma City," EV Narasimha Reddy, managing director of TSIIC said.

Since Telangana has no sea ports, the industries department has proposed a dry port and multi-modal logistic port at Jadcherla, about 30 to 40 km from Pharma City . TSI IC officials claim that they have been getting inquiries from companies across the world for setting up their units at the Pharma City.

"The production cost of pharma products in India is about 30% less than the US and it is 50% less in cases where generic drugs are being developed. Owing to the low costs, multi-national companies are making a beeline to Pharma City ," a senior official of TSIIC said.

January 9th, 2017, 08:41 AM

Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs 970 crore

Quote:

City-based Aurobindo pharma giant Aurobindo Pharma has kicked off the new year with a mega deal, snapping up a Portuguese pharma player Generis Farmaceutica SA from Magnum Capital Partners for a whopping Euro 135 million (Rs 969.3 crore approximately).
This deal comes over two months after Aurobindo lost the bid for Teva's UK & Ireland assets to Ahmedabad-based Intas Pharmaceuticals, which bagged the deal for $764 million (Rs 5,085 crore approx).

bullfrog · January 14th, 2017, 06:21 PM

Singapore-based Surbana Jurong, one of Asia’s largest consultancy companies, has been tasked with assignment.

Hyderabad: The detailed master plan and infrastructure assessment for phase I of the Hyderabad’s Pharma City project will be ready within a fortnight.

The Singapore-based Surbana Jurong, one of Asia’s largest consultancy companies, tasked with the assignment, will be ready with the final draft of the master plan by January 25.

So will be the case with the infrastructure design too. It is being processed under a time-bound programme, according to a senior official in the Industries Department.

The State government which is firm on completing the first phase of the mega project at any cost by 2018 has put the land acquisition process on the fast track.

The Telangana State Industrial Infrastructure Corporation (TSIIC) has identified 18,782.20 acres of land in Rangareddy district and some 5,646.32 acres have already been acquired.

Drone technology for survey
The photogrammetric survey of the entire land parcel was completed using drone technology. The master plan, covering 18,000 acres, is now ready with the TSIIC.

The corporation has focused on the infrastructure development, including external linkages such as power, water, road and rail connectivity. The essential external linkage tie-ups would be finalised by the end of this month.

Moves are afoot to acquire about 2,600 acres of land additionally for phase one of the Pharma City to make increased plot area available for the manufacturing zone.

The government has taken a decision to complete the land acquisition process, to a major extent, by April next, prior to the public hearing on the project.

Environment Impact assessment

The Environment Impact Assessment (EIA) study of the project taken up by the Environmental Protection Training and Research Institute (EPTRI) on December 16 last year has gained momentum. The study would be completed by the end of April. Addressing environmental concerns, the State government has planned the Pharma City project with zero-liquid discharge facilities.

The Common Effluent Treatment Plant (CETP) proposed as part of the project is expected to cost Rs 2,500 crore on Build-own-operate (BOO) model. A financial assistance of Rs 1,500 crore was sought from the Department of Pharma, Government of India.

The Hudco has already sanctioned Rs 740 crores for land acquisition (Rs 550 crore for Pharma City and Rs 190 crores for the National Investment Manufacturing Zone coming up in Medak. So far, Rs 350 crore of the Hudco assistance was already utilised by both the projects.

The techno-economic feasibility report as well as the final application to the Department of Industrial Policy and promotion for the approval of the Centre would also be completed by the end of January.

Preparation of application form, land allotment guidelines, building guidelines are also simultaneously in progress.

The Pharma City, which is a dream project of the government, would emerge as the country’s largest bulk drug manufacturing hub. With proposals for setting up formulation centres, research units and a pharma university taking their final shape, the pharma zone is abuzz with activity.

The Rs 75,000 crore Pharma project will be housing many national and multi-national pharmaceutical companies and life science related companies holding out hope for lakh of jobless youth in the State.

February 6th, 2017, 11:28 AM

Global logistics provider Agility has set up the first temperature-controlled life sciences storage and handling facility at the international airport in Hyderabad.

According to the company, the storage centre, spread across an area of 6,000 square feet, is strategically placed to serve pharmaceutical manufacturers in Hyderabad, Goa, Pune, Visakhapatnam and Bengaluru, the company said.

The center will operate as the primary warehouse for solutions from va-Q-tec, an advanced passive packaging company specialising in high-end, secured cold chain products.

"Life sciences is one of the cornerstones of the Indian economy with exports expected to grow an astonishing 60 per cent in 2017. The new centre will help fast-growing Indian life sciences companies to meet the rising global demand for their products," said Detley Janik, CEO, Agility South Asia.

Agility is one of the largest freight forwarders and logistics providers in India. It operates from 61 locations and controls 1.5 lakh square meters of warehouse space covering all major ports, airports and inland locations in the country

February 7th, 2017, 12:11 AM

Hyderabad: The National Animal Resource Facility for Biomedical Research (NARF) proposed by the Union Ministry of Health and Family Welfare at Genome Valley in the city will be a reality soon.

The Minister for IT and Industries K T Rama Rao will unveil on Monday a model of the Rs 350 crore project taken up by the Indian Council of Medical Research (ICMR) in the 100 acre plot allotted for the first of its kind facility. It would be a new addition to the list of national institutions in the capital.

K T Rama Rao SEZ Genome ValleyFile photo: Minister for IT, Industries and Municipal Administration, K T Rama Rao.Open
He will lay the foundation stone for the Biotech SEZ of the Biological E facility of the M N Park in Genome Valley on the occasion. It will mark the commencement of the three-day 14th BioAsia event in the city. This edition of BioAsia is expected to see the participation of over 800 corporates from 50 countries.

Dr Suresh, Project Director, NARF, told Telangana Today that the institution will create infrastructural facility of international standards for performing pre-clinical testing of new drugs, vaccines, recombinant, herbal products and medical devices within the country.

The NARF will be the certifying authority of Government of India for all drugs, vaccines and pharma products in the country, Dr Suresh said , adding that the institution will also be certifying authority the medical devices and biomedical engineering products as it is a mandatory requirement as per the DCGI norms for approval prior to use in humans.

“It will enable international marketing of our products resulting in increased revenue from the sale of our products abroad,” he added.

sriece19 · February 7th, 2017, 09:41 AM

Stone laid for Biological E.’s new plant near Hyderabad

Quote:

Vaccine maker to invest ₹ 300 cr. on facility at Genome Valley SEZ

: The foundation for a ₹ 300-crore facility of vaccine manufacturer Biological E. Ltd. was laid on Monday in the Special Economic Zone of Genome Valley, on the outskirts of Hyderabad.

The new facility, to come up near the firm’s existing plant, will help augment the vaccine production and add new products. The construction, on about 29 acres, will be completed by April 2018 and commercial production started by December 2019, Managing Director Mahima Datla said.

1,000 jobs to be generated

The investment is part of the ₹ 1,000 crore overall outlay earmarked in the Genome Valley across BE’s vaccines and pharma businesses that are underway.

By the time the company’s expansion initiatives in the Genome Valley are completed, an additional employment opportunity for around 1,000 people would be generated, she said in a release.

Industries and IT Minister K.T. Rama Rao laid the foundation in the presence Worldwide Chairman (Pharmaceuticals) Johnson & Johnson Paul Stoffels, IT Secretary Jayesh Ranjan, Director-General Indian Council of Medical Research Soumya Swaminathan and Medchal MLA M. Sudheer Reddy.

Appreciating the expansion efforts of Biological E., Mr. Rao said that it was one of the foremost pharmaceutical companies of the country based out of Telangana.

In addition to substantial exports of vaccines, it contributed significantly to the Universal Immunisation Programme of the Government of India.

bullfrog · February 7th, 2017, 07:53 PM

Hyderabad: The maiden day of the 14th edition of the state government’s flagship pharma and biotech event – BioAsia 2017 -- attracted investments to the tune of Rs 3,382 crore and also put forth an idea of ‘Genome Valley 2.0’ that can try to replicate Silicon Valley in the area of innovation. Overall, since its inception in 2004, BioAsia has attracted cumulative investments of Rs 14,000 crore.

Giving details about the investments at the inaugural session, Telangana IT, industries, MA & UD, NRI affairs minister KT Rama Rao pointed out that new projects entailing investments of Rs 1,680 crore have been launched at Genome Valley. These include projects such as Biological E's new vaccine unit (Rs 300 crore), MN Park Phase 2 that will build 2 million sft laboratory space (Rs 1,000 crore) and the country’s largest animal resource facility (Rs 330 crore, which is being developed by the government of India in partnership with the state government) and SME hub at ICICI Knowledge Park (Rs 50 crore).

“These initiatives mark the beginning of the next wave of development of Genome Valley 2.0… Genome Valley will very soon compete with the likes of Silicon Valley in terms of innovation and introduction of new drugs and vaccines,” Rao said.

The Telangana government also inked a MoU with PE firm Cerestra to explore a ‘Life Sciences Infrastructure Fund’ with a corpus of Rs 1,000 crore to create a sophisticated modular plug and play infrastructure for pharma, biotech and medical devices industry. The government awarded allotment letters to six pharma companies for setting up or expanding units with a cumulative investment of Rs 702 crore.

The minister also announced that IALA (Industrial Area Local Authority) status will be accorded to Genome Valley soon, which will enable it to create world class infrastructure as well as civic amenities at the campus.

He said that the government has also asked the companies at Genome Valley to switch to renewable energy. Rao also said that he has requested Johnson & Johnson to set up a research centre in Hyderabad and build it as its global innovation hub. The minister also spoke about the government’s ambitious 14,000-acre Pharma City project. To give a glimpse of the overall experience at the Pharma City, an experience zone and virtual reality view of the cluster too has been set up at the BioAsia exhibition.

The government also announced the launch of the TB-Free Telangana Programme, which is a joint initiative of the state government and Johnson & Johnson.

In her address, Soumya Swaminathan, director-general, Indian Council of Medical Research, pointed out that a lot of work also has to be done in the area of nutrition. “If you want the next generation to be healthy -- not just mentally but intellectually-- we need to focus on nutrition,” she said.

Swaminathan also added that it is important for the government to support research of innovator drugs as the initial investment in developing these molecules is high and there is no guarantee of any outcome.

Andhra Pradesh and Telangana governor ESL Narasimhan said that the government along with the industry has to ensure that affordable and accessible healthcare does not stay confined of urban India but also reaches rural India.

At the inaugural, the Genome Valley Excellence Award 2017 was awarded to Nobel Laureate Prof Kurt Wuthrichand and Dr Paul Stoffels, worldwide chairman (pharmaceuticals) and chief scientific officer of Johnson & Johnson.

The 14th edition of BioAsia with a theme of ‘Power of the Past, Force of the Future’, is expected to witness participation from around 1,500 delegates from over 50 countries.

February 8th, 2017, 06:45 AM

New products attract investors at Bio Asia-2017

Quote:

The product was neither on display nor was it associated with a start-up. But the ‘Non-Invasive Haemoglobin Count Device’ received enquiries about its functioning and design by potential investors at the BioAsia-2017 conference. The device was developed by two students and faculty members of the Biomedical Engineering Department of Osmania University. The team put up a stall at the exhibition which was part of the conference.

It took six months for the team to develop the prototype of the product which helps in measuring the haemoglobin concentration in the body in a unique manner. Unlike the conventional method of extracting blood, the process is non-invasive. A person has to wrap a ring-like object around his/her finger and within seconds, the haemoglobin level can be known.

According to M. Venkateswara Rao, associate professor at OU and one of the members of the team, the error in the result vary between 2% and 5%. He said patent has also been applied for, for the product.

“The advantage is that since it is non-invasive, there are less chances of infection. There will also be less bio-waste due to the procedure and a patient does not have to wait for days for the result. The product is highly beneficial in rural areas since the haemoglobin level can be checked by just carrying the equipment,” said Mr. Rao, adding that the device may cost around ₹40,000 if it is commercially produced on a large scale.

Another unique product on display was the ‘Brain Controlled Environment’ that is being developed by the members of Centre for Healthcare Entrepreneurship, IIT Hyderabad. Through the product, the developers aim to empower the paralysed and those who are not in a position to carry out basic activities. According to Santosh Reddy, who is involved in the making of the product, a cap-like device should be worn by the person and depending on his reaction, the tasks will be programmed.

To start with, the members have successfully tested the powering of fans through the blink of an eye.

Already into their eight month, the young science entrepreneurs are working towards making the full-fledged model soon to showcase it to the investors.

sriece19 · February 10th, 2017, 05:26 AM

BioAsia 2017 attracts investments to the tune of Rs. 3,400 crore

Quote:

BioAsia 2017 played host to around 1,200 trade meetings between various organisations and witnessed firming up of investments of around Rs. 3,400 crore.

Summing up the activities during the three-day, 14th edition of the premier forum on biotechnology and life sciences that concluded on Wednesday, Telangana’s IT and Industries Secretary Jayesh Ranjan said the meetings and investments are indicators to the position of Hyderabad in the Life Sciences sector across in the whole country. “We are sure that Hyderabad will continue to work towards increasing its share in global life sciences industry in the coming years,” he said in a release. The event, according to the organisers, saw participation of 1,480 delegates from 51 countries. Figuring among the partnerships firmed up during BioAsia 2017 was the memorandum of understanding between Novartis and the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad. This MoU is for building capabilities and skills, the release said. The forum served as a platform for the Telangana government to showcase its industrial promotion policy as well as major projects proposed in the pharmaceutical sector, including the Pharma City on 14,000 acres on the outskirts of Hyderabad and the Medical Devices and Electronics Park.

IT Minister K.T. Rama Rao held discussion with members of the senior management of some of the leading companies in the healthcare space, including Johnson & Johnson, GSK, Novartis, Glenmark and Wockhardt. The release said, during the meetings he shared details of existing, strong ecosystem that Telangana has and the government’s initiatives to promote cluster-based development to complete the value chain for the Life Sciences sector. The senior executives of the companies evinced interest in Hyderabad from a perspective of a prospective location for the firms’ expansion plans.

In the Startup Showcase, held on the last day of BioAsia 2017, five start-ups showcased their products and services in the field of healthcare, the release said.

February 26th, 2017, 04:35 PM

Hyderabad-based pharma major Granules India Limited is planning to invest $84 million in setting up new capacities, expanding existing ones and investing in R&D to improve its product mix

cyberabad · February 26th, 2017, 04:56 PM

Aurobindo's first Biomanufacturing facility in Hyderabad

Sach4Barca · February 27th, 2017, 08:05 AM

sriece19 · March 9th, 2017, 06:35 AM

GVK to sign pact with govt for operating mobile vet clinics

Quote:

Following the success in operating the 108 ambulance services in the entire State, the GVK group now proposes to introduce ‘mobile veterinary clinics’ in the state.

According to officials, tender process for these ambulances was completed recently. The company is going to sign an agreement for operating 100 vehicles at the constituency level with the government on March 9. The government has earmarked Rs 20 crores for purchase of vehicles.

Soon after the agreement, one vehicle would be operated on pilot basis. The pilot project would provide them with the exact requirements in terms of number of doctors and medicines required to run the service on full scale.

According to officials of Animal Husbandry department, the services will become fully operational from April or May. As per the agreement, each vehicle will have a doctor, animal attendant, a compounder, besides the driver, which costs around Rs 1.5 lakh per vehicle per month, which will be stationed at constituency level.

Even though vehicles will be registered with the government in terms of service, the entire mechanism of handling staff, man power supply and call centre will be run by GVK group.

However, there remains major difference between on how the 108 Ambulance services are being operated by GVK and newly planned mobile veterinary clinics. For 108, the paramedics travel with the vehicle but not the doctors. The paramedics ensure that the condition of the patient does not deteriorate. They ensure that critical care for half-an-hour or maximum of one hour is provided.

While on the other hand the mobile veterinary clinics reaches critical cases of animals under their reach within half an hour. The veterinary doctor in the vehicle will treat the animal, then and there. “The team in the vehicle will be ready with all their equipment to ensure that the animal is treated within the Golden hour,” added the official.

HYDERABAD: The much-vaunted Pharma City, which is proposed to come up at Mucherla on the city's outskirts, seems to be inching closer to reality with the Telangana State Industrial Infrastructure Corporation (TSIIC) gearing up to hold a public hearing next month to kick off the process of securing environmental clearances from the Union ministry of environment and forests (MoEF).

While the Environmental Impact Assessment (EIA) for the Hyderabad Pharma City's first phase, to be spread over 6,000 acres, has already been conducted by the Environmental Protection Training and Research Institute (EPTRI), the master plan for the entire 12,500 acres has been prepared by renowned Singapore-based Surbana Jurong Private Ltd.

"The public hearing for the Pharma City will be held next month. The Telangana Pollution Control Board will give 30 days for filing objections and suggestions before the hearing. The EIA has already been conducted taking all factors into consideration," TSIIC managing director EV Narasimha Reddy told TOI on Tuesday.

TSIIC officials said that once the environmental clearances are granted, the allotment of land will be taken up. Nearly 350 pharma players, including 150 biggies like Pfizer, Johnson & Johnson, Dr Reddy's Laboratories, Zydus Cadila, Mylan and Aurobindo have evinced interest in setting up shop in Pharma City.

While some players have expressed interest through associations such as the Bulk Drug Manufacturers Association (BDMA), others have approached industries minister K T Rama Rao directly, it is learnt.

"Companies have sought land parcels ranging from 10 acres to 200 acres. Most of them are small and medium units that require between 10 to 50 acres. Since pharma firms come under the Red category on account of high pollution generation levels, 33% of the allotted land will have to be earmarked for greenery by each player," said a senior TSIIC official.

"The land allotment will be done by a committee headed by the senior officials of TSIIC, industries department, industry representatives as well as project consultants. The committee will assess the requirement of land to be allocated to each firm," the official added.
If everything goes as per schedule, the Hyderabad Pharma City could well become a reality in a year-and-half.

Natco Pharma plans to increase the production capacity and research & development activity at Rangareddy plant in Telangana

New Delhi: Natco Pharma has received environment clearance (EC) for its Rs480 crore expansion project in Telangana that would generate 1,500 jobs.

The proposal is to increase the production capacity of 66 active pharmaceutical ingredients (APIs) and API intermediates at a time with research and development activity from 115.5 tonnes per annum (TPA) to 645 TPA in the existing land area of 34.17 hectare at Mekaguda village in Rangareddy district.

“The environment ministry has given the final environment clearance to Natco Pharma Ltd for expansion project. The approval has been given based on the recommendations of its expert committee,” a senior government official said.

The environment clearance would be subject to compliance of certain conditions, the official added.

As per the proposal, the cost of the expansion project is estimated to be over Rs480 crore and will provide direct employment to 1,200 and indirect jobs to 300.

Expansion of APIs and API intermediates manufacturing facility will not only increase the market availability of therapeutic drugs but also reduce the import burden on the country, the company said.

The Hyderabad-based company manufactures APIs in bulk quantities for both domestic and global markets. Its products are used in pharmaceutical formulation industry and manufacturing of therapeutic medicines like anti-depressant and anti-psychotic drugs, among others.

Natco Pharma, set up in 1981, has five manufacturing facilities in India. Natco group currently has more than 3,000 employees.

Why is dora and his nephew giving permissions to this poisonous companies?
Andhra Drohulu had spoiled Hyderabad and Telangana with these kind of polluting companies who outsource dumping of chemicals into our fields, forests or even colonies.

They should stop these companies and kick them to andhra. That is what nephew promised us

Quote:

Originally Posted by bullfrog

Source

Natco Pharma plans to increase the production capacity and research & development activity at Rangareddy plant in Telangana

New Delhi: Natco Pharma has received environment clearance (EC) for its Rs480 crore expansion project in Telangana that would generate 1,500 jobs.

The proposal is to increase the production capacity of 66 active pharmaceutical ingredients (APIs) and API intermediates at a time with research and development activity from 115.5 tonnes per annum (TPA) to 645 TPA in the existing land area of 34.17 hectare at Mekaguda village in Rangareddy district.

“The environment ministry has given the final environment clearance to Natco Pharma Ltd for expansion project. The approval has been given based on the recommendations of its expert committee,” a senior government official said.

The environment clearance would be subject to compliance of certain conditions, the official added.

As per the proposal, the cost of the expansion project is estimated to be over Rs480 crore and will provide direct employment to 1,200 and indirect jobs to 300.

Expansion of APIs and API intermediates manufacturing facility will not only increase the market availability of therapeutic drugs but also reduce the import burden on the country, the company said.

The Hyderabad-based company manufactures APIs in bulk quantities for both domestic and global markets. Its products are used in pharmaceutical formulation industry and manufacturing of therapeutic medicines like anti-depressant and anti-psychotic drugs, among others.

Natco Pharma, set up in 1981, has five manufacturing facilities in India. Natco group currently has more than 3,000 employees.

June 7th, 2017, 06:28 PM

'Telangana Medical Devices Park', a dedicated ecosystem for MedTech innovation and manufacturing will be launched at Sultanpur village in Medak district on June 17, the state government announced today.

Telangana Industries Minister KT Rama Rao said Hyderabad which is known for its leadership in bulk drug and life sciences industry, adds another feature to its cap with the launch of a dedicated MedTech Park.

"Hyderabad already has a holistic ecosystem in terms of research facilities, engineering and medical talent, connect between research and medical ecosystem, manufacturing infrastructure, a strong local market, and supply chain and connectivity to all the important global export market," an official release said.

The park, which is coming up in an area of 250 acres, will have facilities to support innovation, research and development, and industrial scale manufacturing, it said.

Education, training, research and incubation facilities to encourage entrepreneurship and innovation ,dedicated social infrastructure for the people working in the cluster will be provided, said the release.

February 7th, 2017, 07:53 PM	#410
bullfrog Registered User Join Date: Dec 2014 Posts: 156 Likes (Received): 35	BioAsia attracts investments worth Rs 3,382 cr on Day-1 Hyderabad: The maiden day of the 14th edition of the state government’s flagship pharma and biotech event – BioAsia 2017 -- attracted investments to the tune of Rs 3,382 crore and also put forth an idea of ‘Genome Valley 2.0’ that can try to replicate Silicon Valley in the area of innovation. Overall, since its inception in 2004, BioAsia has attracted cumulative investments of Rs 14,000 crore. Giving details about the investments at the inaugural session, Telangana IT, industries, MA & UD, NRI affairs minister KT Rama Rao pointed out that new projects entailing investments of Rs 1,680 crore have been launched at Genome Valley. These include projects such as Biological E's new vaccine unit (Rs 300 crore), MN Park Phase 2 that will build 2 million sft laboratory space (Rs 1,000 crore) and the country’s largest animal resource facility (Rs 330 crore, which is being developed by the government of India in partnership with the state government) and SME hub at ICICI Knowledge Park (Rs 50 crore). “These initiatives mark the beginning of the next wave of development of Genome Valley 2.0… Genome Valley will very soon compete with the likes of Silicon Valley in terms of innovation and introduction of new drugs and vaccines,” Rao said. The Telangana government also inked a MoU with PE firm Cerestra to explore a ‘Life Sciences Infrastructure Fund’ with a corpus of Rs 1,000 crore to create a sophisticated modular plug and play infrastructure for pharma, biotech and medical devices industry. The government awarded allotment letters to six pharma companies for setting up or expanding units with a cumulative investment of Rs 702 crore. The minister also announced that IALA (Industrial Area Local Authority) status will be accorded to Genome Valley soon, which will enable it to create world class infrastructure as well as civic amenities at the campus. He said that the government has also asked the companies at Genome Valley to switch to renewable energy. Rao also said that he has requested Johnson & Johnson to set up a research centre in Hyderabad and build it as its global innovation hub. The minister also spoke about the government’s ambitious 14,000-acre Pharma City project. To give a glimpse of the overall experience at the Pharma City, an experience zone and virtual reality view of the cluster too has been set up at the BioAsia exhibition. The government also announced the launch of the TB-Free Telangana Programme, which is a joint initiative of the state government and Johnson & Johnson. In her address, Soumya Swaminathan, director-general, Indian Council of Medical Research, pointed out that a lot of work also has to be done in the area of nutrition. “If you want the next generation to be healthy -- not just mentally but intellectually-- we need to focus on nutrition,” she said. Swaminathan also added that it is important for the government to support research of innovator drugs as the initial investment in developing these molecules is high and there is no guarantee of any outcome. Andhra Pradesh and Telangana governor ESL Narasimhan said that the government along with the industry has to ensure that affordable and accessible healthcare does not stay confined of urban India but also reaches rural India. At the inaugural, the Genome Valley Excellence Award 2017 was awarded to Nobel Laureate Prof Kurt Wuthrichand and Dr Paul Stoffels, worldwide chairman (pharmaceuticals) and chief scientific officer of Johnson & Johnson. The 14th edition of BioAsia with a theme of ‘Power of the Past, Force of the Future’, is expected to witness participation from around 1,500 delegates from over 50 countries.

February 26th, 2017, 04:56 PM	#414
cyberabad Registered User Join Date: Apr 2014 Posts: 669 Likes (Received): 185	Aurobindo's first Biomanufacturing facility in Hyderabad Aurobindo's first Biomanufacturing facility in Hyderabad

RERA & DTCP Approved projects

Saturday, July 31, 2021

Why to invest in Shadnagar |NNR DREAMSCAPE | RERA & DTCP Approved Project |2021|

Our Promises:-

VENTURE FEATURE:-

LOCATION HIGHLIGHTS:-

CONTACT:-

Monday, January 27, 2020

electronic city open plots

MEGA PROJECT IN HARDWARE ELECTRONIC SEZ

HMDA APPROVED OPEN PLOTS @ELECTRONIC SEZ

KRISHNA
9110399207

DESCRIPTION

EV battery facility worth Rs 1500 cr to come up in Telangana

Electric vehicle policy soon, several companies interested in opening factories in Telangana

Push for electric mobility

Force to reckon with

maheswaram updates about Electronic city

SANDSTONE PRESTIGIOUS VENTURE AT MAHESWARAM Special Economic Zone at Maheshwaram gets green clearance in Telangana

FOR SITE VISIT :

Krishna

9110399207

DESCRIPTION

8 km From Hyderabad & Bangalore Highway At Thummalur

Two electronics parks in Telangana get Centre’s nod

While the first is set to come up in Raviryal, the second will come up in Maheshwaram.

Sunday, January 26, 2020

MUCHARLA PHARMA CITY Updates jan 27th 2020

DESCRIPTION

Updates about Pharma city

Report Abuse

February 6th, 2017, 11:28 AM	#407
	Agility opens storage facility for pharma products at Hyderabad airport Global logistics provider Agility has set up the first temperature-controlled life sciences storage and handling facility at the international airport in Hyderabad. According to the company, the storage centre, spread across an area of 6,000 square feet, is strategically placed to serve pharmaceutical manufacturers in Hyderabad, Goa, Pune, Visakhapatnam and Bengaluru, the company said. The center will operate as the primary warehouse for solutions from va-Q-tec, an advanced passive packaging company specialising in high-end, secured cold chain products. "Life sciences is one of the cornerstones of the Indian economy with exports expected to grow an astonishing 60 per cent in 2017. The new centre will help fast-growing Indian life sciences companies to meet the rising global demand for their products," said Detley Janik, CEO, Agility South Asia. Agility is one of the largest freight forwarders and logistics providers in India. It operates from 61 locations and controls 1.5 lakh square meters of warehouse space covering all major ports, airports and inland locations in the country

February 7th, 2017, 12:11 AM	#408
	KTR to unveil NARF project model; To lay stone for Biotech SEZ Genome Valley Hyderabad: The National Animal Resource Facility for Biomedical Research (NARF) proposed by the Union Ministry of Health and Family Welfare at Genome Valley in the city will be a reality soon. The Minister for IT and Industries K T Rama Rao will unveil on Monday a model of the Rs 350 crore project taken up by the Indian Council of Medical Research (ICMR) in the 100 acre plot allotted for the first of its kind facility. It would be a new addition to the list of national institutions in the capital. K T Rama Rao SEZ Genome ValleyFile photo: Minister for IT, Industries and Municipal Administration, K T Rama Rao.Open He will lay the foundation stone for the Biotech SEZ of the Biological E facility of the M N Park in Genome Valley on the occasion. It will mark the commencement of the three-day 14th BioAsia event in the city. This edition of BioAsia is expected to see the participation of over 800 corporates from 50 countries. Dr Suresh, Project Director, NARF, told Telangana Today that the institution will create infrastructural facility of international standards for performing pre-clinical testing of new drugs, vaccines, recombinant, herbal products and medical devices within the country. The NARF will be the certifying authority of Government of India for all drugs, vaccines and pharma products in the country, Dr Suresh said , adding that the institution will also be certifying authority the medical devices and biomedical engineering products as it is a mandatory requirement as per the DCGI norms for approval prior to use in humans. “It will enable international marketing of our products resulting in increased revenue from the sale of our products abroad,” he added.

February 26th, 2017, 04:35 PM	#413
	Hyderabad-based pharma major Granules India Limited is planning to invest $84 million in setting up new capacities, expanding existing ones and investing in R&D to improve its product mix

February 27th, 2017, 08:05 AM	#415
Sach4Barca Registered User Join Date: Aug 2014 Posts: 706 Likes (Received): 429

	#417
	Pharma City inches closer to reality, green nod likely soon HYDERABAD: The much-vaunted Pharma City, which is proposed to come up at Mucherla on the city's outskirts, seems to be inching closer to reality with the Telangana State Industrial Infrastructure Corporation (TSIIC) gearing up to hold a public hearing next month to kick off the process of securing environmental clearances from the Union ministry of environment and forests (MoEF). While the Environmental Impact Assessment (EIA) for the Hyderabad Pharma City's first phase, to be spread over 6,000 acres, has already been conducted by the Environmental Protection Training and Research Institute (EPTRI), the master plan for the entire 12,500 acres has been prepared by renowned Singapore-based Surbana Jurong Private Ltd. "The public hearing for the Pharma City will be held next month. The Telangana Pollution Control Board will give 30 days for filing objections and suggestions before the hearing. The EIA has already been conducted taking all factors into consideration," TSIIC managing director EV Narasimha Reddy told TOI on Tuesday. TSIIC officials said that once the environmental clearances are granted, the allotment of land will be taken up. Nearly 350 pharma players, including 150 biggies like Pfizer, Johnson & Johnson, Dr Reddy's Laboratories, Zydus Cadila, Mylan and Aurobindo have evinced interest in setting up shop in Pharma City. While some players have expressed interest through associations such as the Bulk Drug Manufacturers Association (BDMA), others have approached industries minister K T Rama Rao directly, it is learnt. "Companies have sought land parcels ranging from 10 acres to 200 acres. Most of them are small and medium units that require between 10 to 50 acres. Since pharma firms come under the Red category on account of high pollution generation levels, 33% of the allotted land will have to be earmarked for greenery by each player," said a senior TSIIC official. "The land allotment will be done by a committee headed by the senior officials of TSIIC, industries department, industry representatives as well as project consultants. The committee will assess the requirement of land to be allocated to each firm," the official added. If everything goes as per schedule, the Hyderabad Pharma City could well become a reality in a year-and-half.

	#418
	Natco Pharma gets environment nod for Rs480 crore expansion project in Telangana Natco Pharma plans to increase the production capacity and research & development activity at Rangareddy plant in Telangana New Delhi: Natco Pharma has received environment clearance (EC) for its Rs480 crore expansion project in Telangana that would generate 1,500 jobs. The proposal is to increase the production capacity of 66 active pharmaceutical ingredients (APIs) and API intermediates at a time with research and development activity from 115.5 tonnes per annum (TPA) to 645 TPA in the existing land area of 34.17 hectare at Mekaguda village in Rangareddy district. “The environment ministry has given the final environment clearance to Natco Pharma Ltd for expansion project. The approval has been given based on the recommendations of its expert committee,” a senior government official said. The environment clearance would be subject to compliance of certain conditions, the official added. As per the proposal, the cost of the expansion project is estimated to be over Rs480 crore and will provide direct employment to 1,200 and indirect jobs to 300. Expansion of APIs and API intermediates manufacturing facility will not only increase the market availability of therapeutic drugs but also reduce the import burden on the country, the company said. The Hyderabad-based company manufactures APIs in bulk quantities for both domestic and global markets. Its products are used in pharmaceutical formulation industry and manufacturing of therapeutic medicines like anti-depressant and anti-psychotic drugs, among others. Natco Pharma, set up in 1981, has five manufacturing facilities in India. Natco group currently has more than 3,000 employees.

Saturday, July 31, 2021

Our Promises:-

VENTURE FEATURE:-

LOCATION HIGHLIGHTS:-

CONTACT:-

Monday, January 27, 2020

MEGA PROJECT IN HARDWARE ELECTRONIC SEZ

HMDA APPROVED OPEN PLOTS @ELECTRONIC SEZ

KRISHNA9110399207

DESCRIPTION

EV battery facility worth Rs 1500 cr to come up in Telangana

Electric vehicle policy soon, several companies interested in opening factories in Telangana

Push for electric mobility

Force to reckon with

While the first is set to come up in Raviryal, the second will come up in Maheshwaram.

Sunday, January 26, 2020

DESCRIPTION

KRISHNA
9110399207